Related Experiment Video
Updated: May 6, 2026
Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs
Published on: June 12, 2018
Molecular methods for validation of the biological activity of peptide nucleic acids targeting microRNAs
Eleonora Brognara1, Enrica Fabbri, Nicoletta Bianchi
1Department of Life Sciences and Biotechnology, Ferrara University, Ferrara, Italy.
Abstract:
The involvement of microRNAs in human pathologies is a firmly established fact. Accordingly, the pharmacological modulation of their activity appears to be a very appealing issue in the development of new types of drugs (miRNA therapeutics). One of the most interesting issues is the possible development of miRNA therapeutics for development of anti-cancer molecules. In this respect appealing molecules are based on peptide nucleic acids (PNAs), displaying a pseudo-peptide backbone composed of N-(2-aminoethyl)glycine units and found to be excellent candidates for antisense and antigene therapies. The major limit in the use of PNAs for alteration of gene expression is the low uptake by eukaryotic cells. The aim of this chapter is to describe methods for determining the activity of PNAs designed to target oncomiRNAs, using as model system miR-221 and its target p27(Kip1) mRNA. The effects of PNAs targeting miR-221 are here presented discussing data obtained using as model system the human breast cancer cell line MDA-MB-231, in which miR-221 is up-regulated and p27(Kip1) down-regulated.
Insights
Peptide nucleic acids (PNAs) show promise for anti-cancer drug development by targeting oncomiRs. Researchers developed methods to test PNA activity against miR-221 in breast cancer cells, addressing cellular uptake limitations.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- MicroRNAs (miRNAs) play a crucial role in human diseases, making their pharmacological modulation an attractive therapeutic strategy.
- miRNA therapeutics, particularly for anti-cancer applications, are a significant area of drug development.
- Peptide nucleic acids (PNAs) are promising candidates for antisense and antigene therapies due to their pseudo-peptide backbone.
Purpose of the Study:
- To describe methods for evaluating the activity of PNAs designed to target oncomiRs.
- To use miR-221 and its target p27(Kip1) mRNA as a model system for assessing PNA efficacy.
- To investigate the effects of PNAs targeting miR-221 in a relevant cancer model.
Main Methods:
- Utilizing PNAs with a pseudo-peptide backbone for gene expression alteration.
- Employing a human breast cancer cell line (MDA-MB-231) as a model system.
- Assessing PNA activity by measuring the modulation of miR-221 and its target p27(Kip1) mRNA levels.
Main Results:
- The study presents methods for determining PNA activity against specific oncomiRs.
- Data demonstrates the effects of PNAs targeting miR-221 in MDA-MB-231 cells.
- miR-221 was observed to be up-regulated, and p27(Kip1) down-regulated in the model system.
Conclusions:
- PNAs are effective molecules for targeting oncomiRs, offering potential for novel anti-cancer therapeutics.
- The described methods allow for the assessment of PNA activity in modulating gene expression relevant to cancer.
- Overcoming the limitation of low cellular uptake is key to advancing PNA-based miRNA therapeutics.
